TITLE

Vaccine Development to Prevent Cytomegalovirus Disease: Report from the National Vaccine Advisory Committee

AUTHOR(S)
Arvin, Ann M.; Fast, Patricia; Myers, Martin; Plotkin, Stanley; Rabinovich, Regina
PUB. DATE
July 2004
SOURCE
Clinical Infectious Diseases;7/15/2004, Vol. 39 Issue 2, p233
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Cytomegalovirus (CMV) infection is the most common intrauterine infection in the United States, and it exacts a heavy toll when it infects children and immunocompromised individuals. A CMV vaccine was assigned the highest priority by the Institute of Medicine in its 1999 assessment of targets for vaccine development. The priority was based on the cost and human suffering that would be alleviated by reducing the disease burden of congenital CMV infection. The National Vaccine Advisory Committee and invited experts examined the prospects for a CMV vaccine and the actions needed to bring about successful vaccine development at a National Vaccine Program Office workshop in October 2000. This article summarizes information about the changing epidemiology of CMV and immune responses to infection and immunity, and it reviews the current status of several vaccine candidates. Support of government agencies for CMV vaccine research and development is critical to address this need.
ACCESSION #
13726980

 

Related Articles

  • Immune Responses and Vaccine Development for Cytomegalovirus Infections. Fridkis-Hareli, Masha // British Journal of Medicine & Medical Research;4/1/2014, Vol. 4 Issue 10, p1950 

    Aims: (1) To review the published literature on immune biology of host- Cytomegavovirus (CMV) interactions and to discuss the host immune responses against viral infection, providing insights into the complex interplay between the host and the virus that facilitates viral persistence. (2) To...

  • Experimental vaccine has potential to reduce maternal CMV transmission.  // Infectious Diseases in Children;May2009, Vol. 22 Issue 5, p20 

    The article reports on a phase-2, double blind, placebo-controlled trial which showed that participants who received the experimental cytomegalovirus vaccine containing glycoprotein B and MF59, a squalene-in-water emulsion adjuvant, were significantly less likely to experience an infection...

  • A Subunit Cytomegalovirus Vaccine Based on Recombinant Envelope Glycoprotein B and a New Adjuvant. Pass, Robert F.; Duliege, Anne-Marie; Boppana, Suresh; Sekulovich, Rose; Percell, Sandra; Britt, William; Burke, Rae Lyn // Journal of Infectious Diseases;10/1/99, Vol. 180 Issue 4, p970 

    Describes a cytomegalovirus (CMV) infection vaccine developed from recombitant envelope glycoprotein B. Calculation of the CMV vaccine's effectiveness; Levels of neutralizing antibody; Determination of the optimal dose of the vaccine.

  • Fighting cytomegalovirus-caused diseases: the immunologic approach. Doerr, H. // Medical Microbiology & Immunology;Dec2016, Vol. 205 Issue 6, p511 

    An introduction is presented in which the editor discusses various reports within the issue on topics including approaches to the immunotherapeutic control of cytomegalovirus (CMV) diseases; vaccines to prevent congenital CMV disease; and antiviral function of human-specific T cells.

  • An ounce of prevention.  // New Scientist;6/23/2012, Vol. 214 Issue 2870, p3 

    The article cites a report within the issue about cytomegalovirus (CMV) infections and the risks and benefits of CMV vaccination.

  • Effect of Town Live Virus Vaccine on Cytomegalovirus Disease after Renal Transplant. Plotkin, Stanley A.; Starr, Stuart E.; Friedman, HArvey M.; Brayman, Kenneth; Harris, Sandra; Jackson, Stephanie; Tustin, Nancy B.; Grossman, Robert; Dafoe, Donald; Barker, Clyde // Annals of Internal Medicine;4/1/91, Vol. 114 Issue 7, p525 

    Presents a study that examined the effectiveness of the Towne live virus vaccine among renal transplant patients with cytomegalovirus. Background on cytomegalovirus infection; Examination of the immune responses of patients after vaccination; Estimation of the effectiveness of the vaccine.

  • Exploiting viral natural history for vaccine development. Barry, Peter // Medical Microbiology & Immunology;Jun2015, Vol. 204 Issue 3, p255 

    The partial successes of the Phase 2 gB-based vaccine trials for HCMV highlight the very real likelihood that vaccine-mediated induction of antibodies that neutralize the fusion pathway of fibroblast infection is not sufficient as a singular strategy to confer protective efficacy against primary...

  • The history of vaccination against cytomegalovirus. Plotkin, Stanley // Medical Microbiology & Immunology;Jun2015, Vol. 204 Issue 3, p247 

    Cytomegalovirus vaccine development started in the 1970s with attenuated strains. In the 1980s, one of the strains was shown to be safe and effective in renal transplant patients. Then, attention switched to glycoprotein gB, which was shown to give moderate but transient protection against...

  • Prospects of a vaccine for the prevention of congenital cytomegalovirus disease. Plachter, Bodo // Medical Microbiology & Immunology;Dec2016, Vol. 205 Issue 6, p537 

    Congenital human cytomegalovirus (HCMV) infection is one leading cause of childhood disabilities. Prevention of congenital HCMV disease by vaccination has consequently been identified as a priority public healthcare goal. Several vaccine candidates have been introduced in the past that aimed at...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics